Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Operating Expenses (2019 - 2025)

BridgeBio Pharma's Operating Expenses history spans 7 years, with the latest figure at $293.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 26.66% year-over-year to $293.7 million; the TTM value through Dec 2025 reached $1.0 billion, up 25.85%, while the annual FY2025 figure was $1.0 billion, 25.85% up from the prior year.
  • Operating Expenses for Q4 2025 was $293.7 million at BridgeBio Pharma, up from $265.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $293.7 million in Q4 2025 and bottomed at $128.0 million in Q1 2023.
  • The 5-year median for Operating Expenses is $176.5 million (2022), against an average of $184.7 million.
  • The largest annual shift saw Operating Expenses fell 27.02% in 2023 before it soared 64.68% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $178.5 million in 2021, then fell by 26.55% to $131.1 million in 2022, then surged by 36.66% to $179.2 million in 2023, then grew by 29.44% to $231.9 million in 2024, then grew by 26.66% to $293.7 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Operating Expenses are $293.7 million (Q4 2025), $265.9 million (Q3 2025), and $244.8 million (Q2 2025).